ESMO Congress 2023 | OncologyPRO

Abstract 1603P

Background

The LACE index predicts readmission within 30 days. We evaluated the success of this score in oncological patients for whom hospitalisation is a common condition.

Methods

Between February and July 2022, 188 patients hospitalised in the oncology service of a tertiary referral university hospital were retrospectively screened. Patients admitted for chemotherapy and day care procedures, patients who died during hospitalisation, and subsequent hospitalisation within a month were excluded. LACE scores of the patients were calculated using the length of stay, acuity of the admission, Charlson comorbidity index and emergency Department use six months before admission.

Results

A total of 60 patients were included in the study. Thirty-six (60%) of the patients were under 65 years of age. Most of the patients admitted had gastrointestinal system cancer (n=27, 45%) and lung cancer (n=14, 23.3%), respectively. Twenty-two (36.7%) patients were hospitalised due to infection, and 38 (63.3%) were for palliative care. The median hospital stay of the patients was ten days (min-max: 2-65). The median LACE score of the patients was 11.5 (min-max: 6-16). Fifty-two (%86.7) patients had a high LACE score, eight were in the moderate group, and none were in the low-risk group. Thirty-three (63.5%) of 52 patients with high LACE scores were readmitted to the hospital within 30 days. This rate was statistically significantly higher (p = 0.040) than the moderate group (n=2, 25%). While 55.8% of the patient group with a high LACE score died within 90 days, this rate was (37.5%) in the moderate patient group (p = 0.33).